Cargando…

Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series

Detalles Bibliográficos
Autores principales:	Fu, Dian, Cao, Ruiyuan, Zhao, Lei, Li, Wei, Zhong, Wu, Wen, Jiqiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517732/ https://www.ncbi.nlm.nih.gov/pubmed/32977854 http://dx.doi.org/10.1186/s13054-020-03288-5

Ejemplares similares

Glucocorticoid therapy does not delay viral clearance in COVID-19 patients
por: Ji, Jingjing, et al.
Publicado: (2020)

Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19
por: Fang, Xiaowei, et al.
Publicado: (2020)

Mechanism of action of favipiravir against SARS-CoV-2: Mutagenesis or chain termination?
por: Zhao, Lei, et al.
Publicado: (2021)

Effect of hydroxychloroquine and azithromycin on the viral clearance of SARS-CoV-2: response to Hervé Seligmann
por: Gautret, Philippe, et al.
Publicado: (2021)

Favipiravir in Therapy of Viral Infections
por: Łagocka, Ryta, et al.
Publicado: (2021)

Favipiravir use for SARS CoV-2 infection
por: Boretti, Alberto
Publicado: (2020)

Dysregulation of Innate and Adaptive Immune Responses in Asymptomatic SARS-CoV-2 Infection with Delayed Viral Clearance
por: Cao, Shanshan, et al.
Publicado: (2022)

ICU admission and favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir
por: Peng, Qi, et al.
Publicado: (2021)

Delayed SARS-CoV-2 Clearance in Patients with Obesity
por: Zhang, Xiujun, et al.
Publicado: (2021)

The Anti-Influenza Virus Drug Favipiravir Has Little Effect on Replication of SARS-CoV-2 in Cultured Cells
por: Tomita, Yuriko, et al.
Publicado: (2021)

Re: Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19
por: Jung, Jiwon, et al.
Publicado: (2020)

Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19
por: Masiá, Mar, et al.
Publicado: (2021)

Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series
por: Doi, Kent, et al.
Publicado: (2020)

Lack of viral clearance by the combination of hydroxychloroquine and azithromycin or lopinavir and ritonavir in SARS-CoV-2-related acute respiratory distress syndrome
por: Hraiech, Sami, et al.
Publicado: (2020)

Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis
por: Shannon, Ashleigh, et al.
Publicado: (2020)

Use of Favipiravir in Lactating Mother With COVID-19
por: Karabayır, Nalan, et al.
Publicado: (2021)

Hematological Malignancy Patients, COVID-19, and Favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Model of the RNA Polymerase Complex of the SARS-CoV-2 Virus with Favipiravir
por: Polyakov, I. V., et al.
Publicado: (2021)

Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
por: Solaymani-Dodaran, Masoud, et al.
Publicado: (2021)

The outcomes of favipiravir exposure in pregnancy: a case series
por: Ertem, Ozge, et al.
Publicado: (2022)

Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance
por: Guigon, Aurélie, et al.
Publicado: (2022)

Northern pig-tailed macaques (Macaca leonina) infected with SARS-CoV-2 show rapid viral clearance and persistent immune response
por: Song, Tian-Zhang, et al.
Publicado: (2021)

High-frequency home self-collection of capillary blood correlates IFI27 expression kinetics with SARS-CoV-2 viral clearance
por: Lim, Fang Yun, et al.
Publicado: (2023)

SARS-CoV-2 Viral Clearance and Evolution Varies by Extent of Immunodeficiency
por: Li, Yijia, et al.
Publicado: (2023)

Risk factors for the delayed viral clearance in COVID‐19 patients
por: Chen, Xiaoping, et al.
Publicado: (2021)

Effect of favipiravir and an anti-inflammatory strategy for COVID-19
por: Yamamura, Hitoshi, et al.
Publicado: (2020)

Favipiravir and the Need for Early Ambulatory Treatment of COVID-19
por: Korman, Tony M.
Publicado: (2021)

Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase
por: Shannon, A., et al.
Publicado: (2020)

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2021)

Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir
por: Negru, Paul Andrei, et al.
Publicado: (2022)

Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
por: Hashemian, Seyed MohammadReza, et al.
Publicado: (2022)

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study()
por: Cai, Qingxian, et al.
Publicado: (2020)

Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up
por: Wanschitz, Julia V., et al.
Publicado: (2020)

Can SARS-CoV-2-infected women breastfeed after viral clearance?
por: Lang, Guan-jing, et al.
Publicado: (2020)

Duration of Viral Clearance in Children With SARS-CoV-2 Infection in Rajasthan, India
por: Gupta, Manohar Lal, et al.
Publicado: (2020)

Viral Clearance and Serological Response to SARS-CoV-2 in Kidney Transplant Recipients
por: Silvano, Jos.., et al.
Publicado: (2021)

Cell tropism and viral clearance during SARS-CoV-2 lung infection
por: Schwab, Constantin, et al.
Publicado: (2022)

Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
por: Hifumi, Toru, et al.
Publicado: (2020)

DFT and MD simulation investigation of favipiravir as an emerging antiviral option against viral protease (3CL(pro)) of SARS-CoV-2
por: Yadav, Pooja, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2jfhknic1o5mu74gke3os0dpt6